A Ph1 Randomized Double-Blind Controlled Dose-Range Safety Tolerability & Immunogenicity Study of 2 Doses of Intranasal rH5 Flu Vaccine With & Without Nanoemulsion Adjuvant Followed by 1 Boost of Intramuscular H5N1 Vaccine in Healthy Adults
Latest Information Update: 10 Nov 2025
At a glance
- Drugs BW-1014 (Primary)
- Indications Influenza virus infections
- Focus Adverse reactions; First in man; Pharmacodynamics
- Acronyms IN-NE-rH5
- Sponsors BlueWillow Biologics
Most Recent Events
- 10 Nov 2025 According to BlueWillow Biologics media release, the results from this study were published in Nature Communications.
- 06 Nov 2025 Results published in the Media Release
- 22 Aug 2024 Status changed from active, no longer recruiting to completed.